Product
Mesothelin-Specific Chimeric Antigen Receptor T Cell Injection
1 clinical trial
1 indication
Indication
Ovarian CancerClinical trial
Early-stage Clinical Study of Mesothelin-specific Chimericantigen Receptor T Cells (LD013) in Subjects With Refractory or Relapsed Mesothelin -Positive Ovarian CancerStatus: Completed, Estimated PCD: 2023-02-01